InnoCare Pharma Limited (HKG:9969)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.83
+0.61 (5.44%)
Mar 6, 2026, 4:08 PM HKT
Market Cap23.79B +106.2%
Revenue (ttm)1.56B +58.7%
Net Income-250.97M
EPS-0.16
Shares Out1.70B
PE Ration/a
Forward PE154.51
Dividendn/a
Ex-Dividend Daten/a
Volume6,321,000
Average Volume6,623,327
Open11.19
Previous Close11.22
Day's Range11.19 - 11.85
52-Week Range6.89 - 20.62
Beta0.59
RSI47.18
Earnings DateMar 26, 2026

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 1,176
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9969
Full Company Profile

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.

Financial numbers in CNY Financial Statements